These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34606779)

  • 1. Benchmark dose-response analyses for multiple endpoints in drug safety evaluation.
    Vieira Silva A; Ringblom J; Moldeus P; Törnqvist E; Öberg M
    Toxicol Appl Pharmacol; 2021 Dec; 433():115732. PubMed ID: 34606779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of subchronic toxicity data using the benchmark dose approach.
    Gephart LA; Salminen WF; Nicolich MJ; Pelekis M
    Regul Toxicol Pharmacol; 2001 Feb; 33(1):37-59. PubMed ID: 11259178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of a site-specific reference dose for methylmercury for fish-eating populations.
    Shipp AM; Gentry PR; Lawrence G; Van Landingham C; Covington T; Clewell HJ; Gribben K; Crump K
    Toxicol Ind Health; 2000 Nov; 16(9-10):335-438. PubMed ID: 11762928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does EU legislation allow the use of the Benchmark Dose (BMD) approach for risk assessment?
    Brandon EF; Bulder AS; van Engelen JG; Mahieu CM; Mennes WC; Pronk ME; Rietveld AG; van de Ven BM; Ten Voorde SE; Wolterink G; Slob W; Zeilmaker MJ; Bessems JG
    Regul Toxicol Pharmacol; 2013 Nov; 67(2):182-8. PubMed ID: 23871753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A benchmark dose analysis for sodium monofluoroacetate (1080) using dichotomous toxicity data.
    Foronda NM; Fowles J; Smith N; Taylor M; Temple W
    Regul Toxicol Pharmacol; 2007 Feb; 47(1):84-9. PubMed ID: 16965845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose.
    Barnes DG; Daston GP; Evans JS; Jarabek AM; Kavlock RJ; Kimmel CA; Park C; Spitzer HL
    Regul Toxicol Pharmacol; 1995 Apr; 21(2):296-306. PubMed ID: 7644719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction to benchmark dose methods and U.S. EPA's benchmark dose software (BMDS) version 2.1.1.
    Davis JA; Gift JS; Zhao QJ
    Toxicol Appl Pharmacol; 2011 Jul; 254(2):181-91. PubMed ID: 21034758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the benchmark dose for point of departure determination for a variety of chemical classes in applied regulatory settings.
    Izadi H; Grundy JE; Bose R
    Risk Anal; 2012 May; 32(5):830-5. PubMed ID: 22126138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Silico Models for Repeated-Dose Toxicity (RDT): Prediction of the No Observed Adverse Effect Level (NOAEL) and Lowest Observed Adverse Effect Level (LOAEL) for Drugs.
    Pizzo F; Benfenati E
    Methods Mol Biol; 2016; 1425():163-76. PubMed ID: 27311467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benchmark dose approaches in chemical health risk assessment in relation to number and distress of laboratory animals.
    Oberg M
    Regul Toxicol Pharmacol; 2010 Dec; 58(3):451-4. PubMed ID: 20800084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benchmark dose and the three Rs. Part I. Getting more information from the same number of animals.
    Slob W
    Crit Rev Toxicol; 2014 Aug; 44(7):557-67. PubMed ID: 25000332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats. the impact of increasing the number of dose groups.
    Woutersen RA; Jonker D; Stevenson H; te Biesebeek JD; Slob W
    Food Chem Toxicol; 2001 Jul; 39(7):697-707. PubMed ID: 11397516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing dose-response: I: Critical assessment of the benchmark dose concept.
    Murrell JA; Portier CJ; Morris RW
    Risk Anal; 1998 Feb; 18(1):13-26. PubMed ID: 9523441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of benchmark dose and meta-analysis to determine the most sensitive endpoint for risk assessment for dimethoate.
    Reiss R; Gaylor D
    Regul Toxicol Pharmacol; 2005 Oct; 43(1):55-65. PubMed ID: 16099569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach.
    Bokkers BG; Slob W
    Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.